Invivyd (NASDAQ:IVVD) Director Kevin Mclaughlin Buys 50,000 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Kevin Mclaughlin bought 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the transaction, the director owned 50,000 shares in the company, valued at $125,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Invivyd Stock Down 4.0%

NASDAQ IVVD traded down $0.10 on Thursday, hitting $2.40. The company’s stock had a trading volume of 4,802,679 shares, compared to its average volume of 7,971,830. The company’s 50-day moving average is $1.64 and its 200 day moving average is $1.09. The firm has a market cap of $559.50 million, a PE ratio of -5.11 and a beta of 0.64. Invivyd, Inc. has a 1-year low of $0.35 and a 1-year high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $13.13 million for the quarter, compared to analyst estimates of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, equities analysts expect that Invivyd, Inc. will post -1.64 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in shares of Invivyd during the third quarter valued at approximately $18,831,000. ADAR1 Capital Management LLC bought a new position in shares of Invivyd in the 3rd quarter worth $8,108,000. Vanguard Group Inc. grew its position in Invivyd by 46.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after purchasing an additional 1,834,970 shares during the period. Boothbay Fund Management LLC bought a new stake in Invivyd during the 3rd quarter valued at $894,000. Finally, AQR Capital Management LLC increased its stake in Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Institutional investors own 70.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IVVD shares. Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. D. Boral Capital boosted their target price on shares of Invivyd from $1.00 to $2.00 and gave the company a “buy” rating in a report on Monday, October 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Friday, October 31st. Cantor Fitzgerald initiated coverage on Invivyd in a report on Monday, October 6th. They set an “overweight” rating and a $10.00 price target for the company. Finally, HC Wainwright boosted their price objective on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Invivyd presently has a consensus rating of “Hold” and a consensus target price of $7.33.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.